DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Biological: Adalimumab
Drug: Methotrexate
Drug: Placebo to Methotrexate
Biological: Placebo to Adalimumab

First Posted Date: 2010-12-02

Last Posted Date: 2017-09-25

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 114

Registration Number: NCT01251614

A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Phase 3

Completed

Conditions: Intestinal Behçet's Disease

Interventions: Biological: Adalimumab

First Posted Date: 2010-11-18

Last Posted Date: 2014-07-25

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 20

Registration Number: NCT01243671

Locations: 🇯🇵
Site Reference ID/Investigator# 46725, Nishinomiya-shi, Japan
🇯🇵
Site Reference ID/Investigator# 46728, Nagoya-shi, Japan
🇯🇵
Site Reference ID/Investigator# 46738, Chikushino, Japan

and more 9 locations

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: Adalimumab
Drug: Prednisone
Drug: Azathioprine

First Posted Date: 2010-11-05

Last Posted Date: 2018-01-16

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 252

Registration Number: NCT01235689

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Linifanib
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-10-21

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT01225302

Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)

Completed

Conditions: Chronic Kidney Disease
Secondary Hyperparathyroidism

First Posted Date: 2010-10-20

Last Posted Date: 2014-09-15

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 994

Registration Number: NCT01224782

Locations: 🇧🇬
Site Reference ID/Investigator# 66542, Sofia, Bulgaria
🇧🇬
Site Reference ID/Investigator# 47684, Sofia, Bulgaria
🇷🇴
Site Reference ID/Investigator# 63623, Cluj-Napoca, Romania

and more 66 locations

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Phase 2

Completed

Conditions: Chronic Hepatitis C Infection
Hepatitis C
HCV
Hepatitis C Genotype 1

Interventions: Drug: ABT-450
Drug: ABT-072
Drug: Ribavirin
Drug: Ritonavir

First Posted Date: 2010-10-15

Last Posted Date: 2015-01-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 11

Registration Number: NCT01221298

Locations: 🇺🇸
Site Reference ID/Investigator# 43182, Seattle, Washington, United States
🇺🇸
Site Reference ID/Investigator# 41128, Los Angeles, California, United States
🇺🇸
Site Reference ID/Investigator# 42262, Chicago, Illinois, United States

and more 1 locations

A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee

Phase 2

Completed

Conditions: Osteoarthritis of the Knee

Interventions: Drug: ABT-652
Drug: Naproxen
Drug: Placebo

First Posted Date: 2010-09-22

Last Posted Date: 2013-01-07

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 322

Registration Number: NCT01207115

Locations: 🇺🇸
Site Reference ID/Investigator# 37222, Burbank, California, United States
🇺🇸
Site Reference ID/Investigator# 37227, Milford, Connecticut, United States
🇺🇸
Site Reference ID/Investigator# 37229, Boynton Beach, Florida, United States

and more 35 locations

Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Completed

Conditions: Moderate to Severe Plaque Psoriasis

First Posted Date: 2010-09-16

Last Posted Date: 2014-08-07

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 506

Registration Number: NCT01202565

Locations: 🇨🇿
Site Reference ID/Investigator# 56763, Klimkovice, Czech Republic
🇨🇿
Site Reference ID/Investigator# 63776, Chotoviny, Czech Republic
🇨🇿
Site Reference ID/Investigator# 58083, Jihlava, Czech Republic

and more 70 locations

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: veliparib

First Posted Date: 2010-09-10

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 27

Registration Number: NCT01199224

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Phase 4

Completed

Conditions: Overactive Detrusor
Neurogenic Bladder

Interventions: Drug: Oxybutynin
Drug: Placebo

First Posted Date: 2010-09-01

Last Posted Date: 2024-01-17

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT01192568

Locations: 🇺🇸
Loma Linda University /ID# 236889, Loma Linda, California, United States
🇺🇸
Albany Medical College /ID# 236880, Albany, New York, United States
🇺🇸
Duke University /ID# 237494, Durham, North Carolina, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy